3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Sarcoma
9
Osteosarcoma
4
Sarcoma, Ewing
3
Rhabdomyosarcoma
3
Neuroblastoma
3
Neoplasms
3
Medulloblastoma
3
Glioma
3
Ependymoma
3
Central Nervous System Neoplasms
3
Carcinosarcoma
3
Wilms Tumor
2
Rhabdoid Tumor
2
Recurrence
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioblastoma
2
Endometrial Neoplasms
2
Carcinoma, Endometrioid
2
Breast Neoplasms
2
Xanthogranuloma, Juvenile
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Pathologic Complete Response
1
Interventions
Filgrastim
2
Erlotinib Hydrochloride
2
Docetaxel
2
olaparib
1
lutetium Lu 177 dotatate
1
etoposide phosphate
1
entinostat
1
enasidenib
1
Thalidomide
1
SUB1 protein, human
1
Ritonavir
1
Radiotherapy
1
Peripheral Blood Stem Cell Transplantation
1
Irinotecan
1
Indinavir
1
Ifosfamide
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Fentanyl
1
FPP(RGD)2
1
Etoposide
1
Cyclophosphamide
1
Cryosurgery
1
Cisplatin
1
Cetuximab
1
Carboplatin
1
Capecitabine
1
Amifostine
1
7-hydroxystaurosporine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esthesioneuroblastoma, Olfactory
×
olaparib
×
Sarcoma
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled